Akero Therapeutics to Present at the Jefferies London Healthcare Conference
Akero Therapeutics Advances in MASH Treatment Trials [Yahoo! Finance]
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024